New drug development can take anywhere from 15-30 years and cost over $1B from the start of basic research through the end of clinical trials. With an annual expenditure of $100B per year on research and an average success rate of only 1 out of 12 new treatments reaching end patients, substantial opportunities exist for improving the efficiency of this process and overall patient care.
This talk introduces how Intel is working with scientists and physicians to help improve research, treatment, and drug development for Parkinson’s Disease using data science and enabling the Parkinson’s research community to build upon an open platform for big data analytics
This talk is sponsored by Intel
VP and General Manager, Big Data Solutions
Extended bio link: http://download.intel.com/newsroom/kits/datacenter/pdfs/Ron_Kasabian_Bio.pdf